Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Co-development deal activity surged 1200% between the March–September 2026 period and the prior six months, jumping from zero recorded transactions to 12 signed agreements. The comparison periods — September 2, 2025 through March 2, 2026 (zero deals) versus March 2, 2026 through September 2, 2026 (12 deals) — reveal a market that didn't slowly warm up to co-dev structures; it snapped into them almost overnight. The catalyst: Big Pharma is running out of ways to de-risk late-stage oncology and immunology assets on its own balance sheet, and co-development deals let two parties split the binary risk of a Phase III readout while preserving meaningful economics for both sides.

The Data — Co-Dev Deal Activity, Period over Period

Going from zero to 12 is not a rounding error. This is a structural inflection. Co-development agreements — where two companies share development costs, regulatory responsibilities, and commercial rights — were historically rare because they require deep operational trust and complex governance. The fact that 12 separate pairs of companies decided this was the right structure in a six-month window tells you something important about where the industry's risk appetite currently sits.

What's Driving the Trend

Pipeline compression in oncology is the primary force. Pharma companies are staring at overlapping mechanisms of action across PD-1/PD-L1 combinations, bispecific T-cell engagers, and ADC payloads. The cost of a pivotal oncology trial now routinely exceeds $300M, and the probability of a differentiated label — not just approval, but a label that supports premium pricing — has dropped as the competitive field expands. Co-development structures let two companies pool capital and split that $300M+ binary bet. When your internal IRR model on a solo Phase III shows a risk-adjusted NPV that barely clears the hurdle rate, splitting costs with a partner who brings complementary commercial reach changes the math entirely.

Regulatory complexity is a second driver. The FDA's evolving stance on combination regimens — particularly in immuno-oncology — favors sponsors who can run combination trials with both assets under coordinated INDs. Co-development deals formalize this coordination in a way that simple licensing agreements do not. The agency has signaled through recent guidance drafts that co-development sponsors can share safety databases and streamline BLA submissions, creating a regulatory efficiency that makes the structure more attractive than it was even 18 months ago.

Capital discipline is the third factor. Biotech valuations rebounded modestly in early 2026, but large-cap pharma CFOs remain cautious about committing $1B+ to solo late-stage programs when the same economics can be achieved with a partner absorbing 40–50% of development costs. Co-dev deals are, at their core, a capital allocation tool — and in a market where cost of capital matters again, they're gaining favor over traditional exclusive licenses with large upfront payments. You can track how these structures compare to standard licensing terms using Deal Benchmarks on the Ambrosia platform.

Notable Deals

The clustering is striking: five of the notable deals closed within a 48-hour window in mid-July 2026. This isn't coincidence — it suggests a triggering event, likely a major data readout or regulatory milestone, that prompted multiple parties to formalize agreements that were likely in advanced negotiation.

The AstraZeneca–Merck co-development deal stands out as the most strategically significant. Both companies have deep oncology franchises and established combination strategies. A co-dev structure between two companies of this scale signals that even the largest pharma players see value in sharing risk rather than going solo. This is not a biotech looking for a partner to fund its Phase III — this is two top-10 pharma companies deciding that collaboration beats competition on a specific program.

The Janssen–AbbVie relationship is particularly interesting given the existing Pharmacyclics/AbbVie–Janssen deal signed two days later. AbbVie and J&J/Janssen appear to be building a web of co-development agreements across multiple assets, suggesting a broader strategic alliance rather than one-off transactions. BD teams watching this space should note: when two large companies sign multiple co-dev deals in the same week, it typically signals a framework agreement underneath, with individual asset-level deals flowing from it.

Amgen's dual co-dev deals — with both BeiGene and Novartis — confirm Amgen's strategic pivot toward partnership-heavy development. Amgen's pipeline is rich in bispecific antibodies and next-generation oncology targets, and co-development lets them advance more programs simultaneously without proportionally increasing their development spend. For BeiGene, a co-dev deal with Amgen provides global regulatory credibility and shared infrastructure. For Novartis, it likely fills a mechanism-of-action gap in a competitive therapeutic area.

What This Means for BD Teams Right Now

If you're a biotech with a late-stage asset in oncology or immunology, this is your window. The co-dev deals licensing 2026 environment is the most favorable for originators that we've seen in three years. Big Pharma is actively seeking partners to share development costs, which means they're willing to offer more favorable commercial splits than they would in a traditional out-license. The negotiation leverage has shifted: instead of handing over global rights for an upfront and milestones, you can retain co-promote rights in key markets and share in the upside. Use the Ambrosia calculator to model how co-dev economics compare to a standard license for your specific asset.

If you're on the buy side, move fast. Twelve co-dev deals in six months means the best assets are getting partnered quickly. The July clustering suggests that when deals move, they move in waves — and waiting for the next wave means competing with more bidders. The optimal strategy right now is to identify 3–5 targets where your commercial infrastructure or regulatory expertise adds genuine value to a co-development structure, and approach those companies with a term sheet that emphasizes shared governance and cost-sharing rather than leading with upfront cash.

Deal structures are shifting toward 50/50 cost and profit splits. The traditional 70/30 or 80/20 structures that favored the larger partner are losing ground. When both parties are contributing meaningful capabilities — not just capital — the economics trend toward parity. BD teams should prepare governance frameworks that can handle joint decision-making without creating operational paralysis. The deals that close fastest in this environment are the ones where governance terms are pre-negotiated and clear.

Benchmark your deal against current market rates — the Ambrosia calculator now includes co-development deal templates with cost-sharing and profit-split modeling to help you structure competitive terms.